Welcome to LookChem.com Sign In|Join Free

CAS

  • or

13515-95-2

Post Buying Request

13515-95-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

13515-95-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 13515-95-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,5,1 and 5 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 13515-95:
(7*1)+(6*3)+(5*5)+(4*1)+(3*5)+(2*9)+(1*5)=92
92 % 10 = 2
So 13515-95-2 is a valid CAS Registry Number.

13515-95-2Relevant articles and documents

Synthesis, characterization and topical application of novel bifunctional peptide metallodendrimer

Pandya, Anjali,Patravale, Vandana,Pukale, Sudeep

, (2021/10/30)

Present research work focuses on the synthesis of lower generation bifunctional peptide metallodendrimer followed by its characterization using IR, Mass and NMR (1H and 13C) and finally exploring it for treating acne and wounds. Metallodendrimer was formulated into Tamarind Seed Polysaccharide (TSP) based hydrogel at 7% w/w concentration and analyzed for its properties of spreadability and bioadhesion. Testing of in-vitro antibacterial activity, sterility, in-vivo wound healing efficacy and stability studies followed the formulation development stage. The explored peptide metallodendrimer is a complex of second generation lysine dendrimers and zinc, exhibiting antibacterial activity against Propionibacterium acne, Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. In-vivo wound healing studies in comparison with marketed product indicated significant performance by metallodendrimer with respect to percent re-epithelization and wound contracture. The results were supported by concurrent improvement in various histopathological parameters such as cellularity, granulation, epithelization, vascular density, collagen staining intensity with less number of average mast cells and absence of scar formation. A bifunctional peptide metallodendrimer based platform technology was fabricated and duly evaluated for potential activities.

Supramolecular self-assembly of chiral polyimides driven by repeat units and end groups

Yan, Jijun,Kang, Chuanqing,Bian, Zheng,Jin, Rizhe,Ma, Xiaoye,Gao, Lianxun

supporting information, p. 14723 - 14729 (2017/11/28)

Pyromellitic diimides (PMDIs) are effective building blocks for the construction of supramolecular systems but are infrequently used in comparison with other electron-deficient aromatic systems. We report PMDI-based chiral polyimides that form polymeric supramolecular systems with unique self-assembly features that show time-dependent spectroscopic behaviour. Extensive investigations revealed the driving forces for the self-assembly of the polyimides. One is the complementary aromatic π-π stacking between electron-accepting PMDI and electron-donating phenyl ring in the polymer backbones, and another is the hydrogen bonding interactions of the end groups. The self-assembly is readily disrupted by guest molecules with strong associations with the PMDI and the end groups. The introduction of flexible arylether diimides into the PMDI-based copolymer backbones and the sequence of PMDIs and arylether diimides in the copolymer backbones significantly influence the self-assembly of the polyimides. The results elucidate the mechanisms of polymeric self-assembly of chiral polyimides, providing important information for the development of materials based on polymeric supramolecular systems with properties and functions regulated by composition, sequence and end groups.

NOVEL DRUG DELIVERY CONJUGATED MOIETY FOR ORAL ADMINISTRATION OF DRUG UNSUITABLE FOR ORAL ADMINISTRATION AND PREPARATION METHOD THEREOF

-

Paragraph 70; 71; 72; 73, (2017/02/09)

The present invention provides a novel drug delivery conjugated moiety for oral administration of a drug that is not suitable for oral administration or a pharmaceutically acceptable salt thereof. When the drug delivery conjugated moiety of the present invention or a pharmaceutically acceptable salt thereof is combined with a drug, which is not suitable for oral administration, and is administered orally, it exhibits an excellent absorption rate without decreasing the biological activities of the drug. Moreover, the drug delivery conjugated moiety of the present invention or a pharmaceutically acceptable salt thereof can be easily prepared in a few steps, which is very advantageous in terms of mass production.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 13515-95-2